tirzepatide cause yeast infection GLP-1 Medications & Infections: Clinical Context – PlexusDx Yeast Infection Specialist: Chronic Infection
Description
In the SURPASS-CVOT trial, tirzepatide met its primary endpoint of non-inferiority to dulaglutide for MACE-3, though it lacks an FDA-approved MACE-reduction indication in the U.S.[2] Post hoc cardiorenal analyses examined outcomes beyond the primary MACE endpoint in patients with concurrent cardiovascular and renal risk [3]
There is a trade-off, though
Bennett LL, Fellner C
Thanks to over $600,000 in research funding from the Baszucki Group, this 3-year study will be the first comprehensive investigation into the metabolic biomarkers that can guide psychiatric care
